Skip to main content

Table 4 Recovery time length association with early/late/no drug use

From: Antiviral drugs arbidol and interferon alpha-1b contribute to reducing the severity of COVID-19 patients: a retrospective cohort study

  Drug use Beta (95% CI) P-value
Arbidol Early use vs No use − 5.2 (− 7.5, − 3.0) 4.0E−06
Late use vs No use 1.4 (− 0.1, 2.9) 0.074
Overall use vs No use − 0.1 (− 1.8, 1.6) 0.91
Ribavirin Early use vs No use − 0.3 (− 2.2, 1.59) 0.75
Late use vs No use 3.0 (1.1, 4.8) 0.0018
Overall use vs No use 2.1 (0.5, 3.7) 0.01
IFN-α Early use vs No use − 0.2 (− 2.0, 1.6) 0.82
Late use vs No use 2.2 (− 0.1, 4.4) 0.06
Overall use vs No use 1.4 (− 0.6, 3.4) 0.17
Lopinavir–ritonavir Early use vs No use 4.7 (3.1, 6.2) 1.8E−08
Late use vs No use 7.5 (5.4, 9.6) 1.7E−11
Overall use vs No use 4.1 (2.3, 5.9) 1.4E−05
  1. Association test between patients’ recovery time length against where early drug use or not; late drug use or not. Multivariate linear regression model was used and risk factors and confounding factors were adjusted